Neurological disease biotech company Intellect Neurosciences, Inc. (ILNS) is starting to get the attention of traders as news continues circulating online.
ILNS develops therapy agents to treat and prevent degenerative diseases of the brain. Currently they have several products under license including OX1 and Antisenilin® which are in phase I/II studies. In addition, Intellect Neurosciences has two preclinical products, TauC3, for the treatment of Alzheimers and CONJUMAB-A, for the treatment of amyloidosis.
ILNS has a research collaboration agreement with Medical Research Council Technology and license agreements with South Alabama Medical Science Foundation, New York University, AHP Manufacturing BV, and Northwestern University.
Intellect Neurosciences, Inc. (ILNS) common stock was recently approved for trading on the OTCQB. ILNS stock is currently trading at $0.28 a share with 3.3 million shares outstanding. The 52-week high was $5.00 on Feb. 15 2015 and the low $0.18 on May 27, 2015.